Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Lane

Showing results (141-150 of 265) with videos related to

Pageof 27
Sort By:
FEBS Letters|March 25, 1991
P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanismM C Owen, P M George, D A Lane, et al.
Clinical Nephrology|December 1, 1989
A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparinE Anastassiades, D A Lane, H Ireland, et al.
Blood|March 1, 1985
Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive techniqueD G Connaghan, C W Francis, D A Lane, et al.
British Journal of Haematology|September 1, 1996
Prenatal diagnosis in combined antithrombin and factor V gene mutationD A Lane, K Auberger, H Ireland, et al.
British Journal of Haematology|November 1, 1988
Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222C J Tew, D A Lane, E Thompson, et al.
Thrombosis and Haemostasis|February 1, 1994
Low affinity heparin is an antithrombotic agentE Gray, S Cesmeli, J C Lormeau, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1994
Antithrombin: the principal inhibitor of thrombinR J Olds, D A Lane, B Mille, et al.
The Journal of Biological Chemistry|November 25, 1994
Role of N- and C-terminal amino acids in antithrombin binding to pentasaccharideB Mille, J Watton, T W Barrowcliffe, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1988
Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failureD A Lane, H Ireland, C J Tew, et al.
Blood|December 1, 1990
A frameshift mutation leading to type 1 antithrombin deficiency and thrombosisR J Olds, D A Lane, G Finazzi, et al.
Pageof 27

Showing results (141-150 of 265) with videos related to

Sort By:
Pageof 27
FEBS Letters|March 25, 1991
P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanismM C Owen, P M George, D A Lane, et al.
Clinical Nephrology|December 1, 1989
A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparinE Anastassiades, D A Lane, H Ireland, et al.
Blood|March 1, 1985
Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive techniqueD G Connaghan, C W Francis, D A Lane, et al.
British Journal of Haematology|September 1, 1996
Prenatal diagnosis in combined antithrombin and factor V gene mutationD A Lane, K Auberger, H Ireland, et al.
British Journal of Haematology|November 1, 1988
Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222C J Tew, D A Lane, E Thompson, et al.
Thrombosis and Haemostasis|February 1, 1994
Low affinity heparin is an antithrombotic agentE Gray, S Cesmeli, J C Lormeau, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1994
Antithrombin: the principal inhibitor of thrombinR J Olds, D A Lane, B Mille, et al.
The Journal of Biological Chemistry|November 25, 1994
Role of N- and C-terminal amino acids in antithrombin binding to pentasaccharideB Mille, J Watton, T W Barrowcliffe, et al.
Acta Chirurgica Scandinavica. Supplementum|January 1, 1988
Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failureD A Lane, H Ireland, C J Tew, et al.
Blood|December 1, 1990
A frameshift mutation leading to type 1 antithrombin deficiency and thrombosisR J Olds, D A Lane, G Finazzi, et al.
Pageof 27